Latest News

Scientific Leader Headlines George Clinical Involvement with IIGANN 2021

The International IgA Nephropathy Network held the 16th International Symposium on IgA Nephropathy September 21-23 and George Clinical scientific leader Professor Jonathan Barratt presented a key presentation during the first plenary session of the event. Barratt, the Mayer professor of renal medicine at the University of Leicester, presented “RNA Interference in IgAN” on the first day […]

Read More

September 21st, 2021

George Clinical Recognized as Finalist for Clinical Research Team of the Year Award

Citeline has named George Clinical as a finalist for their 2021 Clinical Research Team of the Year.  Citeline, a comprehensive global R&D intelligence firm provides insights into the global clinical trial landscape and the development of clinical trial programs, selected the DARE-19 team of George Clinical based on their compelling international accomplishments during the height […]

Read More

September 4th, 2021

GSK Sees Positive Results from Five Phase III Studies Conducted with George Clinical for Patients with Anemia Due to Chronic Kidney Disease

GlaxoSmithKline recently announced positive headline results from five studies of the Phase III ASCEND program conducted with George Clinical evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for patients with anemia due to chronic kidney disease (CKD). The ASCEND program showed that daprodustat met its primary […]

Read More

September 2nd, 2021

Conducting Early Phase Trials in the APAC Region

Excellent resources, proven experience and financial incentives make APAC a smart choice for First-in-Human and early phase clinical trials.   Clinical trials are moving east Challenges to conducting trials in the West, especially recruitment difficulties, have made the APAC region a preferred destination for clinical trials. APAC offers a high availability of patients, worldwide accepted […]

Read More

July 30th, 2021

George Medicines Initiates Two Phase III Trials of Triple Combination Candidate to Treat Hypertension

George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death and a sister company to George Clinical, has initiated two Phase III trials investigating its proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension. Recent hypertension guidelines recommend combination therapy as initial […]

Read More

July 16th, 2021

Scientific Leadership Highlighted During 2021 ASCO

George Clinical’s deep oncology research expertise was on display during the 2021 ASCO Annual Meeting. Several leaders were featured in sessions during the conference including Drs. Lee Schwartzberg, Ari VanderWalde, Herbert Loong, Ralph Boccia, Timothy Pluard and Jason Chandler. Schwartzberg is a co-author on 10 different abstracts that were highlighted in sessions during the virtual event […]

Read More

June 24th, 2021

George Medicines Appoints Stefan König as Chief Executive Officer

Sister organization George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announced the appointment of Stefan König as Chief Executive Officer. George Medicines, a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading independent medical research institutes, […]

Read More

June 17th, 2021

George Clinical and Omico Align to Evolve Oncology Study Enrollment Through Genomic Profiling in Australia

SYDNEY, June 15, 2021 – George Clinical, a global scientifically-backed clinical research organization, and Omico, an Australian-based not-for-profit national precision oncology platform, have aligned to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment. The two organizations began collaborating in late 2020 and announced the joint effort during the 2021 […]

Read More

June 15th, 2021

George Clinical Celebrates our Global Team Members on Clinical Trials Day

The important achievements of clinical research around the world hold the potential to improve the health and wellness of humanity. Both leading projects day to day as well going the extra mile behind the scenes stand more than 300 of our dedicated, professional project team members across 38 geographical locations throughout the USA, Asia-Pacific region and […]

Read More

May 21st, 2021

DARE-19 Phase III Collaboration between AstraZeneca, Saint Luke’s Mid America Heart Institute and George Clinical Shows Treatment’s Well-Established Safety Profile Was Consistent in Patients with COVID-19

Detailed results from the primary analysis of the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to treat patients hospitalized with COVID-19 who are at risk of developing serious complications showed that the trial did not achieve statistical significance for the two primary endpoints. However, there were […]

Read More

May 19th, 2021
Sign Up For Our Newsletter

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network